BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 22321781)

  • 21. Comparison of bone marrow and peripheral blood ZAP-70 status examined by flow cytometric immunophenotyping in patients with chronic lymphocytic leukemia.
    Sheridan R; Mounajjed T; Ehrmann DE; Hurtubise PE; Schrager JA
    Cytometry B Clin Cytom; 2006 Jul; 70(4):320-1. PubMed ID: 16906578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion.
    Hernández-Sánchez M; Rodríguez-Vicente AE; Hernández JÁ; Lumbreras E; Sarasquete ME; Martín AÁ; Benito R; Vicente-Gutiérrez C; Robledo C; Heras Nde L; Rodríguez JN; Alcoceba M; Coca AG; Aguilar C; González M; Hernández-Rivas JM
    Leuk Res; 2016 Jul; 46():30-6. PubMed ID: 27111859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-29c down-regulation is associated with disease aggressiveness and poor survival in Chinese patients with chronic lymphocytic leukemia.
    Zhou K; Yu Z; Yi S; Li Z; An G; Zou D; Qi J; Zhao Y; Qiu L
    Leuk Lymphoma; 2014 Jul; 55(7):1544-50. PubMed ID: 24138306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia.
    Heintel D; Kienle D; Shehata M; Kröber A; Kroemer E; Schwarzinger I; Mitteregger D; Le T; Gleiss A; Mannhalter C; Chott A; Schwarzmeier J; Fonatsch C; Gaiger A; Döhner H; Stilgenbauer S; Jäger U;
    Leukemia; 2005 Jul; 19(7):1216-23. PubMed ID: 15858619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression.
    Kopparapu PK; Bhoi S; Mansouri L; Arabanian LS; Plevova K; Pospisilova S; Wasik AM; Croci GA; Sander B; Paulli M; Rosenquist R; Kanduri M
    Epigenetics; 2016 May; 11(5):335-43. PubMed ID: 27052808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features.
    Vrbacky F; Smolej L; Vroblova V; Pekova S; Hrudkova M; Cervinka M; Pecka M; Krejsek J; Maly J
    Hematology; 2010 Aug; 15(4):210-4. PubMed ID: 20670479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression of stereotyped B-cell receptor and its clinical value in chronic lymphocytic leukemia].
    Yu Z; Li ZJ; Yi SH; Zhou KS; Hao M; Li CH; Qi JY; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(46):3267-70. PubMed ID: 22333147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression and prognostic significance of TOSO in CD19+ B cells from Chinese CLL patients].
    Yu Z; Zhou KS; Li ZJ; Yi SH; Hao M; Li CH; Qi JY; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1371-4. PubMed ID: 21756805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia.
    Muñoz L; Lasa A; Carricondo MT; Hernández C; Ubeda J; Nomdedéu JF
    Cytometry B Clin Cytom; 2007 Mar; 72(2):96-102. PubMed ID: 17051526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of molecular and flow cytometric markers in chronic lymphocytic leukaemia.
    Sulda ML; Kuss BJ; Hall RK; Bailey S; Macardle PJ
    Intern Med J; 2012 Feb; 42(2):137-46. PubMed ID: 20561095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
    Rassenti LZ; Huynh L; Toy TL; Chen L; Keating MJ; Gribben JG; Neuberg DS; Flinn IW; Rai KR; Byrd JC; Kay NE; Greaves A; Weiss A; Kipps TJ
    N Engl J Med; 2004 Aug; 351(9):893-901. PubMed ID: 15329427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
    Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
    Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors].
    Xu W; Shen QD; Yu H; Qiao C; Wu YJ; Liu Q; Zhu DX; Miao KR; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):8-12. PubMed ID: 19563027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GALNT11 as a new molecular marker in chronic lymphocytic leukemia.
    Libisch MG; Casás M; Chiribao M; Moreno P; Cayota A; Osinaga E; Oppezzo P; Robello C
    Gene; 2014 Jan; 533(1):270-9. PubMed ID: 24076351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia.
    Vrbacky F; Nekvindova J; Rezacova V; Simkovic M; Motyckova M; Belada D; Painuly U; Jiruchova Z; Maly J; Krejsek J; Zak P; Cervinka M; Smolej L
    Neoplasma; 2014; 61(5):585-92. PubMed ID: 25030442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognostic factors for chronic lymphocytic leukemia with typical and atypical immunophenotype].
    Cao X; Xu W; Wu YJ; Qiao C; Liu Q; Fan L; Miao KR; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jul; 30(7):450-3. PubMed ID: 19954596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome.
    Terrin L; Trentin L; Degan M; Corradini I; Bertorelle R; Carli P; Maschio N; Bo MD; Noventa F; Gattei V; Semenzato G; De Rossi A
    Leukemia; 2007 May; 21(5):965-72. PubMed ID: 17344921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.
    Raval A; Lucas DM; Matkovic JJ; Bennett KL; Liyanarachchi S; Young DC; Rassenti L; Kipps TJ; Grever MR; Byrd JC; Plass C
    J Clin Oncol; 2005 Jun; 23(17):3877-85. PubMed ID: 15809452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
    Klabusay M; Sukova V; Coupek P; Brychtova Y; Mayer J
    Cytometry B Clin Cytom; 2007 Sep; 72(5):363-70. PubMed ID: 17428002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.